Treatment of Osteoporosis in PBC
All patients with PBC and osteoporosis should receive lifestyle modifications, vitamin D supplementation (with correction of deficiency), calcium supplementation if dietary intake is inadequate, and alendronic acid as first-line bisphosphonate therapy 1.
Risk Assessment and Screening
Osteoporosis affects 20-44% of PBC patients, with the majority having osteopenia 1. You must screen all patients with cirrhosis and those with recognized risk factors including female gender, post-menopausal status, low BMI, and older age 1.
Use FRAX (with or without BMD) or QFracture to calculate 10-year fracture risk. If fracture risk approaches intervention threshold, obtain DXA scan and recalculate FRAX with BMD values 1.
Treatment Algorithm
Step 1: Non-Pharmacologic Interventions
- Weight-bearing exercise
- Smoking cessation
- Minimize alcohol intake
- Ensure adequate dietary calcium (1,000-1,200 mg/day) 2
- Falls assessment and referral to specialist falls clinic if history of falls (PBC patients have increased fall risk due to autonomic dysfunction) 1
Step 2: Vitamin D and Calcium
- Correct vitamin D deficiency first 1
- Add calcium supplementation only if dietary intake is inadequate 1
Step 3: Bisphosphonate Therapy
- Alendronic acid is first-line pharmacologic treatment 1
- If patient cannot tolerate alendronate or risedronate, refer to specialist for alternative options 1
Step 4: Alternative Therapies (Specialist Referral Required)
Second-line options include 1:
- Strontium ranelate
- Raloxifene
- Denosumab (60 mg subcutaneously every 6 months)
- Teriparatide
Denosumab is particularly effective and safe in PBC-related osteoporosis, showing 7.5% increase in lumbar spine BMD at 12 months with significantly fewer adverse events (14.3%) compared to zoledronic acid (50%) 3.
Important Clinical Considerations
The concern about oral bisphosphonates causing variceal bleeding is not well-supported by evidence 1. However, if you remain concerned in patients with varices, intravenous bisphosphonates or denosumab are reasonable alternatives.
The pathophysiology of PBC-related osteoporosis differs fundamentally from postmenopausal osteoporosis—it is driven primarily by decreased bone formation rather than increased bone resorption 4. Disease stage and cholestasis severity (elevated bilirubin and bile acids) are the most important risk factors, as these directly impair osteoblast function 5, 6.
Common Pitfalls to Avoid
- Don't wait for advanced cirrhosis to screen—assess all patients with risk factors early
- Don't assume dietary calcium is adequate without assessment
- Don't overlook fall risk assessment—autonomic dysfunction in PBC significantly increases fracture risk beyond bone density alone
- Don't hesitate to use oral bisphosphonates in patients with varices based on theoretical concerns unsupported by strong evidence